drugset / Trial / NCT00051623

A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis

NCT00051623

Phase 3 Completed 70 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if Infliximab is safe and effective in the treatment of psoriatic arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

Timeline

Start
2003-05
Primary completion
Completion
2004-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous
Subject Infliximab Monoclonal antibody 10 mg/kg Intravenous

Indications